Rapid antigen test

Numi Health Provides COVID-19 Testing for Suncor Energy Workers Departing From Edmonton International Airport

Retrieved on:

Monday, May 17, 2021

Medicine, Immunologic tests, Branches of biology, Clinical medicine, S&P/TSX 60, Suncor Energy, Sunoco LP, Alberta Health Services, Calgary, Numi, ELISA, Rapid antigen test

b'CALGARY, Alberta, May 17, 2021 (GLOBE NEWSWIRE) -- Numi Health Inc. (Numi) is pleased to announce a community partnership involving Suncor Energy (Suncor), Edmonton International Airport (EIA) and Alberta Health Services (AHS), in which Numi provides rapid COVID-19 antigen testing for those travelling by air to Suncor\xe2\x80\x99s worksites in northern Alberta.\nSince late April, Numi has been providing rapid antigen testing for Suncor workers each week on charter flights departing from EIA to northern Alberta.

Key Points:

b'CALGARY, Alberta, May 17, 2021 (GLOBE NEWSWIRE) -- Numi Health Inc. (Numi) is pleased to announce a community partnership involving Suncor Energy (Suncor), Edmonton International Airport (EIA) and Alberta Health Services (AHS), in which Numi provides rapid COVID-19 antigen testing for those travelling by air to Suncor\xe2\x80\x99s worksites in northern Alberta.\nSince late April, Numi has been providing rapid antigen testing for Suncor workers each week on charter flights departing from EIA to northern Alberta.
\xe2\x80\x9cRapid antigen testing provides results in as little as 15 minutes, allowing employees to return to work while minimizing concern about contracting or spreading the virus.
We are proud to deliver this industry-leading program to protect the health of Suncor\xe2\x80\x99s team in the field.\xe2\x80\x9d\nThe Suncor project builds on the success of Numi\xe2\x80\x99s screening program for airport workers and travellers.
As EIA\xe2\x80\x99s official COVID-19 testing partner, Numi has been screening hundreds of individuals each week at a pop-up clinic in the main terminal building.

FastLabs Adds New COVID-19 Testing Site at Dolphin Mall

Retrieved on:

Monday, May 17, 2021

b'FastLabs, a leading rapid medical testing company, is now offering patients a site in west Miami-Dade at Dolphin Mall, located at 11401 NW 12 Street in Sweetwater.

Key Points:

b'FastLabs, a leading rapid medical testing company, is now offering patients a site in west Miami-Dade at Dolphin Mall, located at 11401 NW 12 Street in Sweetwater.
This is the second combined location with giant REEF Technology to expand the accessibility of rapid COVID-19 testing.
The Dolphin Mall location will offer fast PCR tests, rapid antigen tests, rapid antibody tests, and a complete flu panel that examines over 19 common respiratory pathogens with results in minutes.\n\xe2\x80\x9cWe are very pleased to be adding this new strategic location,\xe2\x80\x9d said Dr. Raul Cruz, Chief Medical Officer at FastLabs.
Currently focused on COVID-19 testing and other viruses, FastLabs provides express results for those who need fast PCR and rapid testing from the convenience of their vehicles, businesses, or homes.

Quidel’s QuickVue® At-Home OTC COVID-19 Test Now Available for Sale Through Amazon

Retrieved on:

Friday, May 14, 2021

Online Retail, Retail, Medical devices, Health, Infectious diseases, Biotechnology, Medicine, Articles, Branches of biology, Communication, Forward-looking statement, Food and Drug Administration, Rapid antigen test, COVID-19 testing, Severe acute respiratory syndrome coronavirus, COVID-19, XC2, Quidel Corporation

The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.

Key Points:

The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
An innovator for over 40 years in the medical device industry, Quidel pioneered the first FDA-cleared point-of-care test for influenza in 1999 and was the first to market a rapid SARS-CoV-2 antigen test in the U.S.
For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.

CDC Announces COVID-19 At-Home, Rapid Testing Approach Pioneered by eMed for International Travel to Enter the United States

Retrieved on:

Tuesday, May 11, 2021

Medicine, Branches of biology, Life sciences, Medical terminology, Medical tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test, Centers for Disease Control and Prevention, COVID-19

b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.

Key Points:

b'MIAMI, May 11, 2021 /PRNewswire/ -- eMed , a telehealth company, announces updated guidelines by the U.S. Centers for Disease Control and Prevention (CDC) for international airline travelers re-entering the United States.
Passengers may now use eMed\'s pioneering digital-point-of-care platform, offering third-party guided and verified COVID-19 at-home rapid antigen testing with certified results in minutes and automated reporting.\nThe home test administered by eMed provides greater access to individuals needing a reliable, quick and easy rapid antigen test for COVID-19 detection.
"This is an important step in getting validated rapid antigen testing approved for use so international travelers entering the United States may do so with greater ease, in addition to being an important step in our collective efforts to reactivate our economy.
360bbb-3(b)(1), unless the declaration is terminated or authorization is revoked sooner.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/cdc-announces-covid-19-at-home-r...\n'

Government of Canada increases access to COVID-19 rapid testing for workers

Retrieved on:

Friday, May 7, 2021

Medicine, Medical tests, Health, Medical terminology, Occupational safety and health, Chromatography, Molecular biology, Rapid antigen test, Rapid diagnostic test, COVID-19 pandemic, COVID-19

Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.

Key Points:

Workplace screening is another layer of protection for workers, the people they serve and their communities from COVID-19.
Across the country, these rapid tests have already helped to identify and stop the transmission of over 11,000 confirmed cases of COVID-19.\nThis initiative builds on previous successful rapid testing projects supported by the Government of Canada, including through the Creative Destructions Lab Rapid Screening Consortium .
"\n"The Government of Canada is implementing a multi-layered strategy and response to the COVID-19 pandemic through a combination of efforts.
"\nRapid antigen testsalso referred to as rapid screens or rapid testsare easy to administer, and produce results in as little as 15 minutes.

Stop the spread! Could diagnostic antigen tests help control COVID-19 transmission in workplaces?

Retrieved on:

Friday, May 7, 2021

Medicine, Immunologic tests, Branches of biology, Life sciences, Medical terminology, Medical tests, Chromatography, Molecular biology, Rapid antigen test, ELISA, European Centre for Disease Prevention and Control

The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.

Key Points:

The findings are presented in anew joint technical report, which includes a survey of EU-OSHAs focal points on the current use of rapid antigen tests in a workplace context in the EU/EEA.
It builds on the body of knowledge regarding the use of rapid antigen tests provided in ECDC reports.
The report shows that rapid antigen testing can help reduce the spread of the virus in high-risk indoor workplaces.
However, the report stresses that testing cannot replace other safety and health measures and should be used to complement them.

Quidel Forms Retail Collaboration With Walgreens for Over-the-Counter Sale of QuickVue® At-Home OTC COVID-19 Tests

Retrieved on:

Thursday, May 6, 2021

The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.

Key Points:

The shelf-stable packages, each containing two of the self-administered rapid antigen tests, can also be ordered online at Walgreens.com for store pick-up or same day delivery.\n\xe2\x80\x9cThis retail collaboration with Walgreens will expedite in-store availability and over-the-counter sales of our QuickVue At-Home OTC COVID-19 antigen tests to consumers nationwide,\xe2\x80\x9d said Douglas Bryant, president and CEO of Quidel Corporation.
The QuickVue\xc2\xae At-Home OTC COVID-19 Test has not been FDA cleared or approved.
For more information about Quidel, visit quidel.com .\nThis press release contains forward-looking statements within the meaning of the federal securities laws that involve material risks, assumptions and uncertainties.
You are cautioned not to place undue reliance on these forward-looking statements, which reflect management\xe2\x80\x99s analysis only as of the date of this press release.

Kroger Health Launches Over-the-Counter Rapid Antigen Self-Test Kits

Retrieved on:

Wednesday, May 5, 2021

Medicine, Branches of biology, Immunologic tests, Clinical medicine, Biotechnology, Chromatography, Medical terminology, Molecular biology, Rapid antigen test, Kroger, Emergency Use Authorization, COVID-19

b'CINCINNATI, May 5, 2021 /PRNewswire/ --Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the launch of Abbott\'s BinaxNOW COVID-19 Antigen Self Test, an over-the-counter SARS-CoV-2 rapid antigen test that has received FDA Emergency Use Authorization for self-testing without the need for a prescription from a healthcare professional.

Key Points:

b'CINCINNATI, May 5, 2021 /PRNewswire/ --Kroger Health, the healthcare division of The Kroger Co. (NYSE: KR), today announced the launch of Abbott\'s BinaxNOW COVID-19 Antigen Self Test, an over-the-counter SARS-CoV-2 rapid antigen test that has received FDA Emergency Use Authorization for self-testing without the need for a prescription from a healthcare professional.
"Abbott will continue making its BinaxNOW COVID-19 Antigen Self Test available in more national retail settings like Kroger so that people can quickly and easily find the test and get back to living their pre-pandemic lifestyles with more assurance.
To schedule a vaccine appointment, visit here .\nKroger Health also plans to add at-home COVID-19 antigen testing to its employer-focused health and wellness solutions.
Learn more at www.krogerhealth.com .\nAt The Kroger Co. (NYSE:KR), we are Fresh for Everyone and dedicated to our Purpose: ToFeed the Human Spirit.

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

Retrieved on:

Wednesday, May 5, 2021

Medicine, Branches of biology, Medical specialties, Immunologic tests, Blood tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test, Serology, COVID-19, Immunoglobulin G

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.

Key Points:

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.
Offering high sensitivity and specificity, both the Total and IgG tests which have FDA EUA and CE Mark provide public health leaders with an exceptional tool in tracking viral community spread, bolstering serological surveillance efforts, and managing patient treatment pathways.\nOrtho\'s VITROS SARS-CoV-2 Antigen Test, which achieved CE Mark in November 2020 and was authorized for use in the U.S. in January 2021, offers reliable detection of acute COVID-19 infection with high sensitivity and specificity.
The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.\nQuestions from laboratories, health care providers, or government officials regarding Ortho\'s COVID-19 solutions can be directed to: [email protected] .
For more information visit: https://www.orthoclinicaldiagnostics.com/global/covid19/ .\n'

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

Retrieved on:

Wednesday, May 5, 2021

Medicine, Branches of biology, Medical specialties, Immunologic tests, Blood tests, Biotechnology, Chromatography, Molecular biology, Rapid antigen test, Serology, COVID-19, Immunoglobulin G

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.

Key Points:

The company\'s COVID-19 IgG antibody test detects the IgG antibody, which appears in a patient\'s blood in the later phase of infection and remains elevated even after recovery.
Offering high sensitivity and specificity, both the Total and IgG tests which have FDA EUA and CE Mark provide public health leaders with an exceptional tool in tracking viral community spread, bolstering serological surveillance efforts, and managing patient treatment pathways.\nOrtho\'s VITROS SARS-CoV-2 Antigen Test, which achieved CE Mark in November 2020 and was authorized for use in the U.S. in January 2021, offers reliable detection of acute COVID-19 infection with high sensitivity and specificity.
The VITROS SARS-CoV-2 Antigen Test also offers a practical and cost-effective testing alternative to polymerase-chain reaction (PCR) tests, which, while highly accurate, can be expensive and require long processing times during testing surges.\nQuestions from laboratories, health care providers, or government officials regarding Ortho\'s COVID-19 solutions can be directed to: [email protected] .
For more information visit: https://www.orthoclinicaldiagnostics.com/global/covid19/ .\n'